Kevinkumar Kansagra

Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India

Akash Khobragade, Suresh Bhate, Vijendra Ramaiah et al. · The Lancet · 2022 · 248 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India

Taufik Momin, Kevinkumar Kansagra, Hardik B. Patel et al. · EClinicalMedicine · 2021 · 183 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)

Kevinkumar Kansagra, Taufik Momin, Hardik B. Patel et al. · Clinical Pharmacology in Drug Development · 2022 · 73 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study

Kevinkumar Kansagra, Jatin Patel, Shuchi Joshi et al. · American Journal of Nephrology · 2019 · 66 citations

Medicine, Pharmacology, Pharmacotherapy +9

Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study

Anuja Pandit, Nirav Bhalani, Bharat Bhushan et al. · International Journal of Infectious Diseases · 2021 · 65 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +15